SAN CARLOS, Calif. – April 16, 2025 – Glycomine, Inc., a biopharmaceutical company focused on rare diseases, today announced a $115 million Series C financing. This funding will propel its lead candidate, GLM101, into a Phase 2b clinical trial for phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG), a life-threatening genetic disorder with no approved treatments.
The financing was led by CTI Life Sciences Fund, funds managed by abrdn Inc., and Advent Life Sciences, with continued support from existing investors including Novo Holdings, Sanofi Ventures, and Abingworth. The proceeds will enable Glycomine to initiate a randomized, placebo-controlled Phase 2b trial of GLM101 later this year.
GLM101 is a first-in-class mannose-1-phosphate (M1P) replacement therapy. Ongoing Phase 2 study data has shown promising improvements in ataxia, a key symptom of PMM2-CDG. In nine adult and adolescent patients, GLM101 treatment resulted in an average 11.9-point improvement on the ICARS scale over 24 weeks.
Glycomine CEO Steve Axon expressed excitement about the new partnerships and the continued support, stating this funding is “an important step toward bringing the first disease-modifying therapeutic to patients with PMM2-CDG.” Investors highlighted their confidence in Glycomine’s therapeutic approach and the encouraging clinical signals observed. While also exploring mRNA-based enzyme replacement, Glycomine’s current focus is on the M1P replacement approach, leveraging lipid nanoparticles to significantly extend the drug’s half-life.
PMM2-CDG, the most prevalent congenital disease of glycosylation, is caused by a genetic mutation in the PMM2 enzyme, disrupting protein glycosylation and leading to a wide range of severe clinical symptoms.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
